{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:41:00Z","timestamp":1790617260172,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cytokine release syndrome (CRS) is a common adverse event associated with T\u2010cell redirection therapies (TCRT), including talquetamab, the first GPRC5D\u2009\u00d7\u2009CD3 bispecific antibody approved for relapsed\/refractory multiple myeloma (RRMM). We describe CRS with talquetamab and implications for clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients without prior TCRT received talquetamab 0.4\u2009mg\/kg weekly (QW) and 0.8\u2009mg\/kg every other week (Q2W), with two or three step\u2010up doses, respectively, plus pretreatment with a glucocorticoid, antihistamine, and antipyretic. A separate cohort of patients with prior TCRT received talquetamab at either the QW or Q2W schedule. CRS was graded per American Society for Transplantation and Cellular Therapy criteria and managed per study protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Across talquetamab QW (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009143), Q2W (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009145), and prior TCRT (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200951) cohorts, most CRS events occurred during step\u2010up doses and were grade 1 or 2; grade 3 CRS events were rare. Approximately one\u2010third of patients experienced more than one CRS event. Fewer patients experienced subsequent CRS events if tocilizumab was used versus not used to treat their first CRS event. Overall response rates with talquetamab were similar among patients with and without tocilizumab to manage CRS. Baseline characteristics were not associated with CRS incidence, recurrence, duration, or severity, whereas immune biomarkers showed some trends in association with CRS parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CRS outcomes with talquetamab were consistent with those seen with other TCRT in RRMM, including teclistamab (BCMA\u00d7CD3 bispecific antibody), indicating a similar clinical approach, including early vigilance and prompt treatment of CRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>NCT03399799\/NCT04634552<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71276","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:25:37Z","timestamp":1759400737000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Characterization and Management of Cytokine Release Syndrome From the\n                    <scp>MonumenTAL<\/scp>\n                    \u20101 Study of Talquetamab in Patients With Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1002","volume":"14","author":[{"given":"Niels W. C. J.","family":"van de Donk","sequence":"first","affiliation":[{"name":"Amsterdam University Medical Center Vrije Universiteit Amsterdam  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"University of California San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"University of California San Francisco, Helen Diller Family Comprehensive Cancer Center  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center  Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-9649","authenticated-orcid":false,"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"University Hospital of W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Christine","family":"Ye","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center University of Texas  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[{"name":"University College London Hospitals, NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brea","family":"Lipe","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, School of Medicine Wake Forest University  Winston\u2010Salem North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[{"name":"Myeloma Center University of Arkansas for Medical Sciences  Little Rock Arkansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Skerget","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Verona","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Gong","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrajeet","family":"Singh","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Campagna","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Masterson","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi","family":"Hilder","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaszianne","family":"Tolbert","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Renaud","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Damiette","family":"Smit","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heuck","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria\u2010Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"University Hospital of Salamanca\/IBSAL\/CIC\/CIBERONC  Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102016.1.567"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425\u2010018\u20100343\u20109"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1032775"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719899897"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054\u2010017\u20101678\u20101"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34756"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010018\u20100760\u20101"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)00933\u20108"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215949"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(24)00043\u20103"},{"key":"e_1_2_12_14_1","unstructured":"Genentech Inc \u201cACTEMRA\u00ae (Tocilizumab) Injection for Intravenous or Subcutaneous Use \u201dU.S. Food and Drug Administration (2010) updated March 2021 accessed May 8 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125276s131lbl.pdf."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.80"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003342"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805"},{"key":"e_1_2_12_20_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP) \u201cTalvey: EPAR \u2013 Public Assessment Report \u201dEuropean Medicines Agency (2023) updated September 21 2023 accessed October 3 2023 https:\/\/www.ema.europa.eu\/en\/documents\/overview\/talvey\u2010epar\u2010medicine\u2010overview_en.pdf."},{"key":"e_1_2_12_21_1","unstructured":"Janssen Biotech Inc \u201cTALVEY\u2122 (Talquetamab\u2010Tgvs) Injection for Subcutaneous Use \u201dU.S. Food and Drug Administration (2023) updated August 2023 accessed May 8 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf."},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201010\u2010299487"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201005\u2010552729"},{"key":"e_1_2_12_24_1","unstructured":"Johnson & Johson Inc \u201cNDA\/BLA Multi\u2010Disciplinary Review and Evaluation U.S. Food and Drug Administration \u201d(2022) updated December 2022 accessed March 18 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761342Orig1s000MultidisciplineR.pdf."},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8041"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010200344"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015344"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745320"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.447"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmt.2023.01.002"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102020\u2010000621"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010159381"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8033"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152\u20102650(24)01980\u20103"},{"key":"e_1_2_12_35_1","first-page":"705","article-title":"Spotlight on Tocilizumab in the Treatment of CAR\u2010T\u2010Cell\u2010Induced Cytokine Release Syndrome: Clinical Evidence to Date","volume":"16","author":"Si S.","year":"2020","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:10:37Z","timestamp":1765285837000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":36,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/cam4.71276"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71276","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71276"}}